Adaptin Bio (APTN) Cash from Financing Activities (2023 - 2026)

Adaptin Bio has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $438433.0 for Q1 2026.

• Quarterly Cash from Financing Activities fell 90.51% year-over-year to $438433.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 80.39% YoY) and the FY2025 annual result came in at $5.2 million, up 666.71% from the prior year.
• Cash from Financing Activities fell to $438433.0 in Q1 2026, from $582961.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $4.6 million in Q1 2025 and bottomed at -$193876.0 in Q4 2024.
• The 4-year median for Cash from Financing Activities is $330487.5 (2024), against an average of $797296.9.
• Year-over-year, Cash from Financing Activities tumbled 432.28% in 2024 and surged 5033.36% in 2025.
• Adaptin Bio's Cash from Financing Activities stood at $58347.0 in 2023, then tumbled by 432.28% to -$193876.0 in 2024, then surged by 400.69% to $582961.0 in 2025, then retreated by 24.79% to $438433.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $438433.0, $582961.0, and $4.6 million for Q1 2026, Q4 2025, and Q1 2025 respectively.